Gamma Knife Market

Global Gamma Knife Market Size (2024 to 2029)

As per our report, the size of the global gamma knife market was worth USD 295.56 million in 2024 and is estimated to be growing at a CAGR of 8.79% to reach USD 450.39 million by 2029.

Gamma knife is one of the types of radiation therapy used to treat brain tumors and other brain abnormalities with the help of computerized software. It is mainly used in high-risk brain treatment due to delivering intense radiation doses to the target area. The market size is estimated to expand due to the highest use in brain metastasis. Gamma knife radiosurgery can be included with chemotherapy, radiation therapy, and brain surgery. Food and drug administration has approved gamma knife surgery for the last 50 years for brain diseases, and it is a cost-saving treatment compared to other conventional therapy.

MARKET DRIVERS

Y-O-Y rise in the incidence of brain tumors and cancer, coupled with the increasing adoption of gamma knife, is majorly propelling the growth of the global gamma knife market.

According to the data published by the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, and an estimated 9.6 million died from cancer in 2018. According to the National Brain Tumor Society, around 0.7 million people in the United States now suffer from brain tumors, and over 87,000 cases will be joining the count by 2020. As mentioned in the lines discussed above, the growing prevalence of cancer and brain tumors is primarily accelerating the growth of the global gamma knife market. Several medical device manufacturers focus on developing gamma knife instruments due to the rising patient population of central nervous system tumors and brain tumors worldwide.

The usage of gamma knife radiosurgery increases in treating brain tumors, epilepsy, neurological disorders, malformations, and other central nervous system disorders, which is estimated to boost the global gamma knife market significantly. The rising prevalence of cancer, obesity, the aging population, and the growing number of people suffering from brain metastasis, neuralgia, and other diseases further accelerate the market's growth. Additionally, the increasing usage of gamma knife instruments in surgical cancer centers is also lavishing the growth rate of the global gamma knife market. 

The advantages associated with the gamma knife are to support the market expansion during the forecast period.

Compared to standard cancer treatment methods, using a gamma knife brings several advantages. Gamma knife does not require the patient to be admitted to the hospital after the procedure; it also helps the patients recover faster and more efficiently. Gamma knife procedure also leads to fewer risks and low exposure to radiation to other parts of the brain. Gamma knife is a powerful and advanced treatment procedure, and it is preferred due to its positive results.

MARKET RESTRAINTS

Side effects and high costs associated with gamma knife instruments are the most significant restraints to the growth of the global gamma knife market. Furthermore, the lack of skilled workers in the healthcare industry further hinders the gamma knife market. Additionally, the market is also hindered by the stringent set of rules and regulations imposed by the governments for the approval of gamma knife instruments, making it difficult for manufacturers to clear clinical trial approvals.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Gamma Knife Market By Disease Indication

The Brain metastasis segment holds the largest market share for gamma knives based on disease indication, accounting for more than sixty percent of the share. Brain metastasis is a problem when cancer spreads from its origin to the brain, and the latest prevalence of the condition brings revenue to the market. The condition can also be referred to as a brain tumor, and an estimated 72,360 adults age 40+ are predicted to be diagnosed with a primary brain tumor in 2023 in the U.S.

However, the cancer segment is also expected to show fast growth due to the rise in cancer cases worldwide. In addition, cases of malicious tumors are expected to support the rise of the market. According to WHO stats, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Therefore, the prevalence of the problem has led to more revenue for the segment. The other segment is also expected to incur revenue during the market.

REGIONAL ANALYSIS

Regionally, the Asia Pacific gamma knife market had the leading share in the global gamma knife market, followed by the North American and Europe regions. Since many cancer centers in the United States offer the latest gamma knife technology, Asia Pacific has a top spot in the global market. This is due to the availability of good healthcare facilities, an increase in people with neurological conditions, and an aging population.

The North American gamma knife market is expected to have the fastest growth rate during the forecast period, owing to India and China's growing patient base and economies. However, during Pacific region is expected to overtake the North American region during the forecast period. With the increased use of gamma knife machines, the Asia Pacific market is expected to be the fastest developing in the coming years. These developed countries are investing more in R&D and upgrading their healthcare systems. It's also been noticed that the local community is becoming more aware of Gamma Knife and its applications. Increased disease incidence, rising cancer and brain tumor prevalence growing awareness among healthcare practitioners about non-invasive treatment options, high adoption of these instruments in surgery centers, and expanding healthcare infrastructure in this area contribute to this region's rapid growth.

The European gamma knife market accounted for a substantial global market share in 2023. Rising healthcare spending and favorable reimbursement programs boost the overall regional market's expansion to a large extent. In addition, the growing prevalence of cancer in Europe is improving the Gamma Knife demand in the area. According to the World Health Organization, Europe has just one-eighth of the world's population. However, the field accounts for about a quarter of all cancer cases worldwide.

The Latin American gamma knife market is expected to hold a considerable share of the global market during the forecast period.

The gamma knife market in the Middle East and Africa is estimated to grow at a moderate CAGR during the forecast period.

KEY MARKET PARTICIPANTS

Some of the prominent companies leading the global gamma knife market profiled in this report are Varian Medical Systems, Elekta AB, Cyber Medical Corporation Ltd., Huiheng Medical Inc., Masep Infini Global, Inc., Hokai, Nordion Inc., ET Medical Group and American Shared Hospital Services.

RECENT MARKET DEVELOPMENTS

• In October 2022, The CyberKnife System for treating trigeminal neuralgia was certified for payment by the Japanese Ministry of Health, Labor, and Welfare (MHLW), according to Accuray Incorporated's announcement today (TN). The technology offers a compelling new alternative for persons with this chronic pain illness, which some patients describe as the most unbearable pain a person can endure.
• In October 2022, Healthcare organizations in the United States now have access to two imports from across the Atlantic that is of interest to medical imagers. First, 3D LifePrints, based in Liverpool, United Kingdom, received FDA approval for their EmbedMed craniomaxillofacial platform. According to a press release the business released earlier this month, surgeons who treat facial, skull, and cranial problems can plan, perform, and assess surgeries using patient-specific models made from imaging scan data.
• In August 2022, the most cutting-edge Gamma Knife platform, now complying with EU regulations, will aid people with brain disorders, cancer, and other malignancies. In addition, Elekta announced that their Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform, has earned the CE mark. So, this regulatory clearance is the first step toward enabling people with brain diseases in Europe and other nations that accept the CE mark—then later the rest of the world—to obtain therapy with this cutting-edge device.
• In May 2022, more individualized radiosurgery with sub-millimeter accuracy and treatment planning taking less than 60 seconds will be possible with the next-generation Gamma Knife. In addition, with the introduction of Elekta Esprit, Elekta has advanced radiosurgery to a previously unheard-of degree. This most recent and cutting-edge system will provide clinicians with automated treatment planning that is substantially faster, more individualized, and patient-friendly treatments, and a level of precision that can safeguard the person and the mind.
• In 2019, the University of Minnesota Health was come up with the latest next-generation gamma knife radiosurgery to treat brain tumor patients. The gamma knife icon is an advanced type of radiosurgery targeting treatment.
• In 2020, Elekta launched their new Leksell gamma knife lightening to treat stereotactic radiosurgery, an automatic system treatment planning solution that includes beam-on time constraints.

DETAILED SEGMENTATION OF THE GLOBAL GAMMA KNIFE MARKET INCLUDED IN THIS REPORT

This research report on the global gamma knife market has been segmented and sub-segmented based on the disease indication and region.

By Disease Indication

• Brain Metastasis   
• Cancer      
• Trigeminal Neuralgia           
• VM (Arteriovenous Malformation)           
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa